Sommaire

• • ·Table of Contents

    Page :A1

    
• • ·Editorial Board

    Page :A6

    
• • ·Information for Readers

    Page :A7

    

• Editorial

  • ·Geographic variations of acute heart failure syndromes : The importance of clinical registries

    Page :1-2

    Hector O. Ventura, Krishna K. Gaddam

    

• Progress in Cardiology

  • ·Phase II trials in heart failure: The role of cardiovascular imaging

    Page :3

    Sanjiv J. Shah, Gregg C. Fonarow, Mihai Gheorghiade, Roberto M. Lang

    Résumé Résumé Plan Plan  
  • ·Ischemic heart disease: Comprehensive evaluation by cardiovascular magnetic resonance

    Page :16-30

    Theodoros D. Karamitsos, Erica Dall'Armellina, Robin P. Choudhury, Stefan Neubauer

    Résumé Résumé Plan Plan  

• Curriculum in Cardiology

  • ·Differential impact of race and risk factors on incidence of atrial fibrillation

    Page :31-37

    T. David Gbadebo, Henry Okafor, Dawood Darbar

    Résumé Résumé Plan Plan  
  • ·Diagnosis and management issues in thoracic aortic aneurysm

    Page :38

    Anna M. Booher, Kim A. Eagle

    Résumé Résumé Plan Plan

• Trial Design

  • ·A multicenter, randomized, controlled study of mechanical left ventricular unloading with counterpulsation to reduce infarct size prepercutaneous coronary intervention for acute myocardial infarction: Rationale and design of the Counterpulsation Reduces Infarct Size Acute Myocardial Infarction trial

    Page :47

    Manesh R. Patel, Holger Thiele, Richard W. Smalling, Praveen Chandra, Yi Zhou, Marc Cohen, Divaka Perera, Erik Magnus Ohman

    Résumé Résumé Plan Plan  
  • ·The ?-3 fatty acids for Prevention of Post-Operative Atrial Fibrillation trial—rationale and design

    Page :56

    Dariush Mozaffarian, Roberto Marchioli, Tim Gardner, Paolo Ferrazzi, Patrick O'Gara, Roberto Latini, Peter Libby, Federico Lombardi, Alejandro Macchia, Richard Page, Massimo Santini, Luigi Tavazzi, Gianni Tognoni

    Résumé Résumé Plan Plan  

• Cardiac Safety Research Consortium

  • ·Troponin measurements during drug development—considerations for monitoring and management of potential cardiotoxicity : An educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug Administration

    Page :64-73

    L. Kristin Newby, Ignacio Rodriguez, John Finkle, Richard C. Becker, Karen A. Hicks, Elizabeth Hausner, Ruth Chesler, Courtney Harper, Shari Targum, Brian R. Berridge, Eric Lewis, Dana B. Walker, Colin Dollery, J. Rick Turner, Mitchell W. Krucoff

    Résumé Résumé Plan Plan

• Clinical Investigations

  • ·Prevalence and correlates of smoking cessation pharmacotherapy in hospitalized smokers with acute myocardial infarction

    Page :74-80

    David A. Katz, Fengming Tang, Babalola Faseru, Phillip A. Horwitz, Philip Jones, John Spertus

    Résumé Résumé Plan Plan  
  • ·Improved diagnostic and prognostic performance of a new high-sensitive troponin T assay in patients with acute coronary syndrome

    Page :81-88

    Michael Weber, Oscar Bazzino, Jose Luis Navarro Estrada, Raul de Miguel, Simon Salzberg, Juan J. Fuselli, Christoph Liebetrau, Mariella Woelken, Helge Moellmann, Holger Nef, Christian Hamm

    Résumé Résumé Plan Plan  
  • ·Cardiogenic shock and heart failure post–percutaneous coronary intervention in ST-elevation myocardial infarction: Observations from “Assessment of Pexelizumab in Acute Myocardial Infarction”

    Page :89-97

    John K. French, Paul W. Armstrong, Eric Cohen, Neal S. Kleiman, Christopher M. O'Connor, Anne S. Hellkamp, Amanda Stebbins, David R. Holmes, Judith S. Hochman, Christopher B. Granger, Kenneth W. Mahaffey

    Résumé Résumé Plan Plan  
  • ·Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

    Page :98

    Jeffrey S. Berger, Deepak L. Bhatt, P. Gabriel Steg, Steven R. Steinhubl, Gilles Montalescot, Mingyuan Shao, Werner Hacke, Keith A. Fox, Peter B. Berger, Eric J. Topol, A. Michael Lincoff

    Résumé Résumé Plan Plan  
  • ·Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial

    Page :106

    Michelle A. Albert, Robert J. Glynn, Francisco A.H. Fonseca, Alberto J. Lorenzatti, Keith C. Ferdinand, Jean G. MacFadyen, Paul M Ridker

    Résumé Résumé Plan Plan  
  • ·Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: A meta-analysis of randomized trials

    Page :115

    Jeffrey S. Berger, Anuradha Lala, Mori J. Krantz, Gizelle S. Baker, William R. Hiatt

    Résumé Résumé Plan Plan  
  • ·Practice variability and outcomes of coil embolization of aortopulmonary collaterals before fontan completion: A report from the Pediatric Heart Network Fontan Cross-Sectional Study

    Page :125-130

    Puja Banka, Lynn A. Sleeper, Andrew M. Atz, Collin G. Cowley, Dianne Gallagher, Matthew J. Gillespie, Eric M. Graham, Renee Margossian, Brian W. McCrindle, Charlie J. Sang, Ismee A. Williams, Jane W. Newburger

    Résumé Résumé Plan Plan  
  • ·Growth differentiation factor 15: An additional diagnostic tool for the risk stratification of developing heart failure in patients with operated congenital heart defects?

    Page :131-135

    Kambiz Norozi, Reiner Buchhorn, Abeer Yasin, Siegfried Geyer, Lutz Binder, Jamie A. Seabrook, Armin Wessel

    Résumé Résumé Plan Plan
  • ·Resting cardiac energy metabolism is inversely associated with heart rate in healthy young adult men

    Page :136-141

    Gabriele Fragasso, Francesco De Cobelli, Roberto Spoladore, Antonio Esposito, Anna Salerno, Giliola Calori, Claudia Montanaro, Francesco Maranta, Guido Lattuada, Alberto Margonato, Alessandro Del Maschio, Gianluca Perseghin

    Résumé Résumé Plan Plan  
  • ·The Romanian Acute Heart Failure Syndromes (RO-AHFS) Registry

    Page :142

    Ovidiu Chioncel, Dragos Vinereanu, Mihai Datcu, Dan Dominic Ionescu, Radu Capalneanu, Ioan Brukner, Maria Dorobantu, Andrew Ambrosy, Cezar Macarie, Mihai Gheorghiade

    Résumé Résumé Plan Plan  
  • ·Atrial fibrillation and mortality in African American patients with heart failure: Results from the African American Heart Failure Trial (A-HeFT)

    Page :154-159

    Judith E. Mitchell, S. William Tam, Kamini Trivedi, Anne L. Taylor, Welton O'Neal, Jay N. Cohn, Manuel Worcel

    Résumé Résumé Plan Plan  
  • ·The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET/OFFSET and RESPOND studies

    Page :160-165

    Kevin P. Bliden, Udaya S. Tantry, Robert F. Storey, Young-Hoon Jeong, Martin Gesheff, Cheryl Wei, Paul A. Gurbel

    Résumé Résumé Plan Plan  
  • ·Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use

    Page :166

    Deepak Voora, John Horton, Svati H. Shah, Linda K. Shaw, L. Kristin Newby

    Résumé Résumé Plan Plan
  • ·Changes in reference vessel diameter in ST-segment elevation myocardial infarction after primary percutaneous coronary intervention: Implications for appropriate stent sizing

    Page :173-177

    Ecaterina Cristea, Gregg W. Stone, Roxana Mehran, Ajay J. Kirtane, Sorin J. Brener

    Résumé Résumé Plan Plan  
  • ·Association of initial Thrombolysis in Myocardial Infarction flow grade with mortality among patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A National Registry of Myocardial Infarction-5 (NRMI-5) analysis

    Page :178-183

    Jinhui Wu, Yuri B. Pride, Paul D. Frederick, C. Michael Gibson

    Résumé Résumé Plan Plan
  • ·Body mass index and health status in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial (BARI 2D)

    Page :184

    Sheng-Chia Chung, Mark A. Hlatky, Roslyn A. Stone, Jamal S. Rana, Jorge Escobedo, William J. Rogers, Joyce T. Bromberger, Sheryl F. Kelsey, Maria Mori Brooks

    Résumé Résumé Plan Plan  
  • ·Long-term results of atrial fibrillation ablation: The importance of all initial ablation failures undergoing a repeat ablation

    Page :193-200

    Roger A. Winkle, R. Hardwin Mead, Gregory Engel, Rob A. Patrawala

    Résumé Résumé Plan Plan  

• Letters to the Editor

  • ·Optimizing electrocardiographic interpretation in acute ST-elevation myocardial infarction may be very beneficial

    Page :e1

    Antoni Bayés de Luna, Diego Goldwasser, Victoria de Porta, Miguel Fiol-Sala, Andrés Carrillo, Javier Garcia-Niebla, Antoni Bayés-Genis

    
  • ·Appropriate cardiac catheterization laboratory activation: Optimizing electrocardiogram interpretation and clinical decision making for acute ST-elevation myocardial infarction

    Page :e3

    Yochai Birnbaum, James M. Wilson, Kjell Nikus

    
  • ·Appropriate cardiac catheterization laboratory activation: Author reply

    Page :e5

    Ivan C. Rokos, William J. French, Amal Mattu, Michael Farkouh, James Reiffel, Gregg W. Stone

    
  • ·Acute hyperglycemia: Is really a new risk marker for contrast-induced nephropathy in patients with acute myocardial infarction without diabetes and normal renal function?

    Page :e7

    Sergio Raposeiras-Roubín, Cristina Barreiro Pardal, Raimundo Ocaranza, Belén Cid, José Ramón González-Juanatey

    
  • ·Author's reply to Acute hyperglycemia: Is really a new risk marker for contrast-induced nephropathy in patients with acute myocardial infarction without diabetes and normal renal function?

    Page :e9

    Giancarlo Marenzi, Monica De Metrio, Antonio L. Bartorelli

    
  • ·Regarding “The EVEREST II Trial: Design and rationale for a randomized study of the Evalve MitraClip system compared with mitral valve surgery for mitral regurgitation”

    Page :e11

    Mustafa Cikirikcioglu, Sanjay Cherian, Olivier Schussler, Afksendiyos Kalangos

    
  • ·In response to the letter to the editor of Cikirikcioglu et al regarding “The EVEREST II Trial: Design and rationale for a randomized study of the Evalve MitraClip system compared with mitral valve surgery for mitral regurgitation”

    Page :e13

    Laura Mauri, Donald Glower, Elyse Foster, Ted Feldman

    
  • ·Liver transaminase levels alone could not be the optimal method to estimate hepatic safety after statin administration in patients with chronic kidney disease

    Page :e15

    Christian Molino, Ruana Tiseo, Alfredo De Giorgi, Marco Pala, Roberto Manfredini

    
  • ·Standard versus high loading doses of clopidogrel in Asian patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: Insights from the Korea Acute Myocardial Infarction Registry

    Page :e17

    Gen-Min Lin, Yi-Hwei Li, Kai-Min Chu, Chih-Lu Han

    
  • ·Do East Asians have different hypercoagulable states compared with Western population?

    Page :e19

    Young-Hoon Jeong, Kevin P. Bliden, Udaya S. Tantry, Paul A. Gurbel

    Plan Plan
  • ·Response to the letter regarding the article “Do East Asians have different hypercoagulable states compared with Western population?”

    Page :e21

    Cheol Ung Choi, Seung-Woon Rha, Dong Joo Oh, Kanhaiya L. Poddar, Jin Oh Na, Jin Won Kim, Hong Euy Lim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Taek Jong Hong, Jong-Seon Park, Young Jo Kim, Seung Ho Hur, In Whan Seong, Jei Keon Chae, Myeong Chan Cho, Jang Ho Bae, Dong Hoon Choi, Yang Soo Jang, In Ho Chae, Hyo Soo Kim, Chong Jin Kim, Jung Han Yoon, Tae Hoon Ahn, Seung-Jea Tahk, Wook Sung Chung, Ki Bae Seung, Shung Chall Chae, Seung Jung Park, Young Keun Ahn, Myung Ho Jeong